Core Viewpoint - *ST Baoying has been found to have internal control deficiencies in engineering management, procurement management, and fund management, leading to regulatory actions from the Shenzhen Securities Regulatory Bureau [2][3] Group 1: Regulatory Actions - The Shenzhen Securities Regulatory Bureau has issued a decision requiring *ST Baoying to correct its internal control issues and has issued warning letters to key executives including the chairman and general manager [3] - The company is required to submit a written rectification report within 30 days [4] Group 2: Company Overview - *ST Baoying was established on April 30, 1993, with a registered capital of 1.516 billion RMB and is headquartered in Shenzhen [4] - The company provides integrated solutions including construction and decoration engineering [4] Group 3: Financial Performance - The company's projected revenues for 2024 and 2025 are 2.112 billion RMB, 824.51 million RMB, and 312 million RMB, showing year-on-year declines of 48.63%, 89.37%, and 74.35% respectively [6] - The net profit attributable to the parent company for the same periods is projected to be -742 million RMB, -16.20 million RMB, and -23.76 million RMB, with year-on-year growth rates of 23.52%, 77.67%, and 89.38% respectively [6] - The asset-liability ratios for the years are 100.46%, 101.97%, and 102.14% [6] Group 4: Risk Profile - The company has a total of 659 internal risks and 3109 external risks, with 125 historical risks and 631 warning alerts [6]

Group 1 - The Shenzhen Stock Exchange issued a regulatory letter to Shenzhen Baoying Construction Holding Group Co., Ltd. and its executives regarding deficiencies in internal controls related to project management, procurement management, and fund management [1] - The company was found to have inaccurate disclosures regarding cash donations from related parties in December 2024, violating multiple articles of the Stock Listing Rules and self-regulatory guidelines [1] - The executives, including the former chairman and general manager, were held responsible for failing to fulfill their duties and obligations, emphasizing the need for strict compliance with laws and regulations [1] Group 2 - Lin Yuan, a notable figure in the investment community, expressed confidence in the market despite recent losses, stating that he will continue to invest and believes in the demand for liquor as a "pleasure need" [2] - He also mentioned that investments in technology stocks have caused him significant concern, indicating a cautious approach towards this sector [2]

Core Viewpoint - Road and Bridge Information has faced significant financial reporting issues, leading to a drastic reduction in its projected net profit for 2024 by 84.91% due to major internal control deficiencies identified by the Xiamen Securities Regulatory Bureau [1][2][3]. Financial Adjustments - The company announced a correction of accounting errors, adjusting its 2024 revenue from 240 million yuan to 215 million yuan, a decrease of 25.76 million yuan, or 10.71% [3]. - The net profit for 2024 was revised from 22.48 million yuan to 3.39 million yuan, a reduction of 19.09 million yuan, equating to a decline of 84.91% [3]. - The adjusted net profit after deducting non-recurring items fell from 19.52 million yuan to 425,400 yuan, a staggering drop of 97.82% [3]. Previous Year Adjustments - For 2023, the company's revenue was adjusted from 238 million yuan to 222 million yuan, a decrease of 15.84 million yuan [4]. - The net profit for 2023 was revised from 21.58 million yuan to 8.57 million yuan, reflecting a decline of 60.29% [4]. Regulatory Actions - The Xiamen Securities Regulatory Bureau mandated the company to rectify its financial reporting practices due to violations of the Securities Law of the People's Republic of China and related disclosure regulations [2]. - The company is required to engage a qualified accounting firm to provide a special verification report on the corrections made [4].

Core Viewpoint - Guosheng Technology (603778.SH) has been penalized by the China Securities Regulatory Commission for multiple violations, leading to corrective measures for the company and several key personnel [2][4]. Group 1: Violations and Penalties - Guosheng Technology has been found to have inaccurate revenue and cost recognition in its landscaping business, resulting in misleading disclosures in the 2022 annual report and the 2023 semi-annual report [4][5]. - The company failed to follow proper procedures for external borrowing, with a subsidiary misclassifying a loan of 87.5 million yuan as project prepayment without reporting to management [4][5]. - Internal controls in the newly added lighting business segment were inadequate, with multiple management deficiencies identified [4][5]. Group 2: Responsible Personnel - Key personnel held responsible for the violations include Huai Quanfu (former Chairman and General Manager), Wu Jun (former Chairman), Gao Fei (former General Manager), Zhang Yongsheng (former CFO), and Yao Qi (former CFO) [5]. - The Shanghai Stock Exchange has issued a regulatory warning to Guosheng Technology and the aforementioned individuals, mandating effective corrective actions and a thorough review of compliance risks [5]. Group 3: Financial Performance - In the first half of 2025, Guosheng Technology reported revenue of 307 million yuan and a net loss attributable to shareholders of 96.34 million yuan [5].

Core Viewpoint - Guosheng Technology has received regulatory warnings from the Shanghai Stock Exchange due to multiple violations, including inaccurate cost recognition in its landscaping business and failure to follow proper procedures for external loans [1][2]. Group 1: Violations Identified - The company inaccurately recognized costs related to its landscaping business, leading to incorrect disclosures in the 2022 annual report and the 2023 semi-annual report [1]. - A subsidiary of Guosheng Technology treated a loan of 87.5 million yuan as an engineering prepayment without reporting it to the management or following the necessary approval and disclosure procedures [1]. - There were deficiencies in internal controls related to the newly added photovoltaic business, including management of the entire EPC process, supplier qualifications, inventory management, and external loans [1]. Group 2: Responsible Individuals - Key individuals held responsible for the violations include the former Chairman and General Manager, the current Chairman, the former General Manager, and the former Financial Directors, who failed to adhere to relevant regulations and commitments [2]. Group 3: Required Actions and Compliance - The company and its executives are required to take effective measures to rectify the identified violations and conduct a thorough review of compliance risks in information disclosure and operational norms [3]. - Guosheng Technology must submit a rectification report signed by all executives to the exchange within one month of receiving the decision [3]. - The company is mandated to comply with legal regulations and stock exchange rules, ensuring proper disclosure of all significant information [3].

Core Viewpoint - ST HuLuWa Pharmaceutical, once known as "China's top children's medicine brand," is currently facing severe challenges, with significant declines in revenue and profit reported in its 2025 semi-annual report [2][3]. Financial Performance - In the first half of 2025, ST HuLuWa achieved operating revenue of 508 million yuan, a year-on-year decrease of 42.89% [2]. - The net profit attributable to shareholders was 2.41 million yuan, down 94.14% year-on-year, while the net profit after deducting non-recurring gains and losses turned into a loss of 18.78 million yuan, a decline of 514.52% [2]. - The decline in performance is attributed to market demand fluctuations and intensified industry competition, particularly in the sales of respiratory medications [2]. Core Business Challenges - The core business segment of ST HuLuWa has experienced a severe downturn, with respiratory medications generating revenue of 299 million yuan, accounting for 58.86% of total revenue but down 52.91% year-on-year [3]. - Digestive system medications generated 109 million yuan, representing 21.46% of revenue, while systemic anti-infection medications brought in 49.51 million yuan, making up 9.74% of revenue [3]. Expense Structure - Sales expenses decreased significantly to 107 million yuan, down 60.25% year-on-year, accounting for 21.06% of revenue [4]. - Financial expenses increased to 21.07 million yuan, a rise of 77.74% year-on-year, primarily due to interest expenses from loan capitalized after project completion [4]. - R&D expenses were drastically reduced to 19.38 million yuan, down 80.69% year-on-year, attributed to the confirmation of R&D expenses based on progress [4]. Asset Quality - As of June 30, 2025, ST HuLuWa had cash and cash equivalents of 169 million yuan, a decrease of 33.65% from the end of 2024, mainly due to reduced cash receipts from sales [4]. - Accounts receivable increased to 455 million yuan, up 19.71% from the beginning of the period, with longer collection cycles due to the "two-invoice system" policy [5]. Regulatory Issues - ST HuLuWa faces serious challenges beyond performance declines, including issues with financial credibility and internal control deficiencies [6]. - In March 2025, the Hainan Securities Regulatory Bureau issued administrative measures against ST HuLuWa for non-compliance in revenue recognition and pricing, leading to significant adjustments in previously reported profits [6]. - The company adjusted its net profit for 2023 and the first half of 2024 by approximately 95.64 million yuan and 37.66 million yuan, respectively, revealing that much of the previously reported profit was not from genuine business activities [6]. Audit Concerns - In April 2025, the accounting firm Li Xin issued a qualified opinion on ST HuLuWa's 2024 financial report and a negative opinion on its internal control audit [6]. - The audit revealed that the controlling shareholder provided funds to customers through non-employee personal accounts, raising concerns about the collectability of large accounts receivable [6]. - ST HuLuWa purchased eight R&D projects from an affiliated company for 42.05 million yuan, which has ties to the actual controller, raising questions about the commercial rationale and potential financial impact of these transactions [7].

Core Viewpoint - Longjin Technology (300594.SZ) is under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, following an internal control audit that identified deficiencies in financial management and related party transactions [1][3][4]. Financial Performance - For the first half of 2025, Longjin Technology reported revenue of 340 million yuan, a year-on-year decrease of 10.88%. However, the net profit attributable to shareholders was 1.4764 million yuan, a significant increase of 106.77% compared to the previous year [1][9]. - The company achieved a net profit of 300,500 yuan after excluding non-recurring gains and losses, marking a 101.37% year-on-year increase [1][9]. - Longjin Technology had previously incurred losses for three consecutive years, with cumulative losses of 138 million yuan and 151 million yuan for net profit and net profit excluding non-recurring items, respectively [9]. Internal Control Issues - An internal control audit conducted four months prior revealed that Longjin Technology had deficiencies in financial payment approvals, related party transaction decision-making, and information disclosure [1][4]. - The audit report highlighted that the controlling shareholder, Longjin Group, and its subsidiaries had non-operationally occupied funds amounting to 229 million yuan, which have since been fully repaid [1][4][5]. Shareholding and Pledges - As of June 30, 2025, Longjin Group directly held 19.035 million shares of Longjin Technology, accounting for 20.72% of the total share capital, with a pledge rate of 55.69% [2][7]. - Among the shares held by Longjin Group, 10.6 million shares were pledged, and 2.7 million shares were frozen [7]. Market Reaction - Following the announcement of the investigation, Longjin Technology's stock price fell over 14% intraday on August 28, closing down 9.45% at 17.82 yuan per share [4].

Core Viewpoint - Shenzhen Securities Regulatory Bureau has decided to take regulatory talk measures against HNA Futures Co., Ltd. due to multiple internal control deficiencies and violations of regulations [3][4]. Group 1: Regulatory Findings - HNA Futures failed to effectively manage internet marketing activities and supervise internet marketing personnel, leading to inadequate internal controls and incomplete inspection materials [3]. - The company has deficiencies in its asset management business-related systems and lacks essential auditing functions in its office system logs [3]. Group 2: Accountability - Cheng Qingfang, as the Chairman and General Manager, is held responsible for the company's violations due to not fulfilling his duties effectively [3]. - Liu Yanxin, the Chief Risk Officer, did not adequately supervise the company's compliance and risk management, failing to report existing issues [3]. - Zhang Likun, responsible for internet marketing from December 2023 to June 2025, is also held accountable for the violations [4]. - Song Xiaocheng, the Deputy General Manager, failed to manage internet marketing activities effectively [4]. Group 3: Regulatory Actions - Regulatory measures include issuing warning letters to Cheng Qingfang, Liu Yanxin, and Zhang Likun, while Song Xiaocheng will receive a regulatory talk [4].

Core Points - The company received an administrative regulatory measure from the Dalian Bureau of the China Securities Regulatory Commission on August 14, 2025, due to internal control deficiencies [1][2] - The identified issues include problems in fund management, procurement management, and contract management within the company and its wholly-owned subsidiary, Shenyang Bai'ao Chemical Co., Ltd. [1][2] - The chairman Liu Xianwu and the financial director Wang Xiliang are held primarily responsible for these violations of the Corporate Governance Code and internal control guidelines [2] Regulatory Actions - The company is required to take corrective actions and submit a written report within 30 days of receiving the decision [2][3] - Liu Xianwu and Wang Xiliang will receive warning letters, which will be recorded in the securities market integrity archives [2] - The company emphasizes that these regulatory measures will not affect its normal production and management activities [3] Company Response - The company acknowledges the issues and commits to actively rectify them while enhancing internal management and compliance with securities laws [3] - The board of directors, supervisors, and senior management will strengthen their understanding of relevant regulations to improve operational standards [3]

Core Viewpoint - The company, Changyuan Technology Group Co., Ltd., is under scrutiny from the Shanghai Stock Exchange regarding its 2024 annual report due to issues related to non-operating fund occupation by related parties, leading to significant internal control deficiencies and accounting errors [1][2][3]. Group 1: Related Party Fund Occupation - The company’s chairman, Wu Qiquan, is linked to Zhuhai Yuntaili Holdings Co., Ltd., which has been identified as occupying company funds through third parties [1][2]. - The annual audit revealed that the auditors could not obtain sufficient evidence to identify all related parties, resulting in a qualified opinion on the financial statements [1][3]. - The company has acknowledged the need to correct accounting errors related to non-operating fund occupation in its financial reports for 2023 and 2024 [1][3]. Group 2: Supplier Information and Financial Data - The company identified seven suppliers involved in fund occupation, detailing their establishment dates, major financial data, and actual controllers [2][3][4]. - For example, Zhuhai Chengbangda has total assets of 261.73 million yuan and a net profit of 5.5 million yuan as of December 31, 2024 [3][4]. - The company has initiated self-inspections and requested confirmations from these suppliers regarding their actual controllers and any potential fund occupation [4][5]. Group 3: Internal Control Deficiencies - The company has recognized significant internal control deficiencies in its fund payment approval and related party transaction processes [1][2][3]. - Contracts and payments related to the identified suppliers were executed without proper authorization, leading to difficulties in detecting fund occupation [1][2][3]. - The company plans to implement corrective measures and hold responsible personnel accountable for these deficiencies [2][3][5]. Group 4: Financial Adjustments and Reporting - The company has made retrospective adjustments to its financial statements for the years 2023 and 2024 to reflect the impact of the identified accounting errors [1][2][3]. - The adjustments include changes to monetary funds, other receivables, and credit impairment losses [1][2][3]. - The company has committed to adhering to accounting standards and ensuring timely disclosures of any further adjustments needed [1][2][3].